In contrast, for the scFv(FRP5)-ETA molecule utilizing the different FRP5 antibody domain, we could previously show that local treatment of cutaneous lesions of ErbB2-expressing tumors by intratumoral injection of the scFv(FRP5)-ETA molecule was well tolerated, and resulted in shrinkage or complete regression of injected tumor nodules in the majority of patients [23]. The gene discussed is ERBB2; the disease is neoplasm.